EXCLUSIVE: NLS Pharma CEO Comments On Notice Of Allowance For U.S. Patent Application Covering Its Proprietary Mazindol Formulation, Tells Benzinga Co. Remains 'on track to initiate our prospective Phase 2 clinical study for Quilience'